Aaron Berg - 26 Jun 2025 Form 4 Insider Report for AMARIN CORP PLC\UK (AMRN)

Reporting relationship: President and CEO
Issuer ticker: AMRN
Reported as of: 26 Jun 2025
Net transaction value: -$609,972
SEC form: 4
Accepted by SEC: 30 Jun 2025, 21:30:04 UTC
Prior SEC filing: 31 Jan 2025
Next SEC filing: 03 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Provoost, by power of attorney

Key filing fact

Aaron Berg filed Form 4 for AMARIN CORP PLC\UK (AMRN) on 30 Jun 2025.

Key facts

This page summarizes Aaron Berg's Form 4 filing for AMARIN CORP PLC\UK (AMRN).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 30 Jun 2025, 21:30.

Change

Previous filing in this sequence was filed on 31 Jan 2025.
Current net transaction value: -$609,972.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001770259 Primary reporting owner

Berg Aaron

Relationship: President and CEO
Address: C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER
Signature: /s/ Jonathan Provoost, by power of attorney
Signature date: 30 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMRN transaction

American Depositary Share

Options Exercise

Transaction value
Shares: +75,000
Change %: +170%
Price
Shares after: 119,077
Date: 26 Jun 2025
Ownership: Direct
Footnotes: F1, F2, F3

AMRN transaction

American Depositary Share

Tax liability

Transaction value: $609,972
Shares: -38,363
Change %: -32%
Price: $15.90
Shares after: 80,714
Date: 26 Jun 2025
Ownership: Direct
Footnotes: F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMRN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +37,500
Change %
Price: $0.000000
Shares after: 37,500
Date: 26 Jun 2025
Ownership: Direct
Underlying class: American Depositary Shares
Underlying amount: 37,500
Exercise price: $15.90
Footnotes: F1, F5

AMRN transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +75,000
Change %
Price: $0.000000
Shares after: 0
Date: 26 Jun 2025
Ownership: Direct
Underlying class: American Depositary Shares
Underlying amount: 75,000
Exercise price: $0.000000
Footnotes: F1, F2, F3, F6, F7

AMRN transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +12,500
Change %
Price: $0.000000
Shares after: 12,500
Date: 26 Jun 2025
Ownership: Direct
Underlying class: American Depositary Shares
Underlying amount: 12,500
Exercise price: $0.000000
Footnotes: F1, F3, F6, F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change.

Footnote F2

On June 26, 2025 the Reporting Person was granted 75,000 RSUs that vested as of the June 26, 2025.

Footnote F3

Not applicable.

Footnote F4

Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.

Footnote F5

On June 26, 2025 the Reporting Person was granted an option to purchase 37,500 American Depositary Shares ("ADS") under the Plan. The shares subject to this option shall vest and become exercisable over eighteen months, with 50% to vest on the first anniversary of the grant date and the remaining balance to vest eighteen months after grant date.

Footnote F6

Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion.

Footnote F7

Additionally, award was exercise or conversion of derivative security exempted pursuant to Rule 16b-3.

Footnote F8

On June 26, 2025, the Reporting Person was granted 12,500 RSUs that vests in two equal installments on the first anniversary of the grant date and the remaining balance to vest eighteen months after grant date.